Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Valente Pinto

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Lancet. Infectious Diseases|November 28, 2017
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trialDavid Goldblatt, Jo Southern, Nick J Andrews, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Molecular Systems Biology|November 19, 2020
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccineDaniel O'Connor, Marta Valente Pinto, Dylan Sheerin, et al.
Nature Communications|March 8, 2024
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussisJoshua Gillard, Madeleine Suffiotti, Peter Brazda, et al.
Ebiomedicine|March 1, 2021
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United KingdomPauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Frontiers in Immunology|June 9, 2022
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three CountriesPauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, et al.
Journal of Immunological Methods|October 1, 2024
A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigensMarta Valente Pinto, Alex-Mikael Barkoff, Sagida Bibi, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Lancet. Infectious Diseases|November 28, 2017
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trialDavid Goldblatt, Jo Southern, Nick J Andrews, et al.
The Lancet. Infectious Diseases|January 11, 2021
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trialKimberly Davis, Marta Valente Pinto, Nick J Andrews, et al.
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Molecular Systems Biology|November 19, 2020
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccineDaniel O'Connor, Marta Valente Pinto, Dylan Sheerin, et al.
Nature Communications|March 8, 2024
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussisJoshua Gillard, Madeleine Suffiotti, Peter Brazda, et al.
Ebiomedicine|March 1, 2021
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United KingdomPauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Frontiers in Immunology|June 9, 2022
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three CountriesPauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, et al.
Journal of Immunological Methods|October 1, 2024
A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigensMarta Valente Pinto, Alex-Mikael Barkoff, Sagida Bibi, et al.
Pageof 2